Expertise

no-image

EVERSANA Team

EVERSANA employs a team of over 2500 professionals across 27 locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter the most to our clients and perform superior services that create value across the product life cycle.

Articles by EVERSANA Team

WODC Insights: Developing HEOR Programs for Orphan Drugs

To successful launch a new orphan drug, demonstration of therapeutic success is crucial for a global HTA submission and securing market access. Manufacturers need to create a compelling value story with real-world data to illustrate how the therapy positively impacts the patient journey. In his informative presentation from the World Orphan Drug Congress 2020, Chris […]

NEXT GENERATION COMMERCIALIZATION: A CONVERSATION WITH THE INNOVATORS

Sell, out-license or launch internally: these are the three traditional options to commercialize a pharmaceutical product. Selling and out-licensing are common but cause innovators to lose ownership in an investment that takes years to develop. Launching internally requires an average investment of $125MM+ before the product even hits the shelves. Until now, there was no […]

WODC 2020 Insights: Leveraging AI/ML to Advance Rare Diseases

Leveling the playing field The average time to correctly diagnose a patient with a rare disease is 7 years, largely due to data sparsity, misdiagnoses, incorrect prescriptions, etc. Now, through the application of artificial intelligence and machine learning algorithms, we are able to shorten the time to diagnoses of rare diseases and even discover undiagnosed […]

Navigate the Complexity of Proposed CMS Medicaid Rule

In this presentation at MDRP’s virtual summit, Mike Kurland discusses several key regulatory proposals and executive orders and the impact on pharma: Operationalizing Value-Based Contracting – Has the door been opened, and how do we prepare for an increase in value-based strategies? Managing Coupons and Vouchers – Do we have the right data, and what […]

How to Get Your Digital Therapeutic Approved & Reimbursed in Europe and the U.S.

Patients, providers, and payers expect healthcare to be more accessible, intuitive, and adaptable to their needs. Barriers that have held back innovation in Digital Medicine and Telemedicine have been blasted apart with the recent relaxing of CMS and HHS requirements, continuing advances within the FDA’s Digital Health program, and additional reimbursement opportunities emerging globally. Get […]

PharmaVOICE100 Recognizes Two EVERSANA Leaders

For the past 15 years, PharmaVOICE has celebrated leaders throughout the life sciences industry who provide inspiration to their peers, colleagues and companies through their innovative and motivational approaches to addressing the industry’s myriad challenges. As defined by PharmaVOICE these individuals: set industry trends and create opportunities out of obstacles; are innovative and have the […]

WODC 2020 Insights: Innovative Value and Access Strategies

Innovative rare disease therapies deserve innovative value and access strategies.  With over 1,500 attendees from 50+ countries, the World Orphan Drug Congress featured four days of education, conversation and brainstorming dedicated to drug development and commercialization. EVERSANA’s CEO, Jim Lang, had the esteemed honor of hosting Pfizer’s Vice President of Rare Disease, Patient & Health […]

The New Gold Standard of Drug Commercialization

The First & Only Go-To Complete Commercialization Expert Manufacturers spend >$125MM over three years leading up to launch, yet 66% of drugs don’t meet launch expectations. An unpredictable landscape, coupled with inevitable industry pressures, is forcing manufacturers to seek a more complete commercialization approach with less risk and more value. In 2018, EVERSANA, a leading […]

The Importance of Digital Strategy in Pharma in the APAC Region

The Asia Pacific region continues to show great progress in digital health as pharmaceutical companies look at digital technologies as a tool to drive access and to start developing their digital strategies. To understand the strides and recent evolution of digital in pharma, our APAC team conducted a survey with top pharmaceutical companies in the […]

Improving Patient Outcomes Through Digital Health

Digital applications can work cohesively with therapeutics in the treatment of a broad range of diseases, from behavioral health to chronic conditions. In an interview with Debraj Dasgupta, Head of Strategy & Go-to-Market Planning at Nippon Boehringer Ingelheim Co., Ltd., Ed Cox, Executive Vice President, Strategic Alliances & Global Head of Digital Medicine at EVERSANA, […]

The Digitalization of Healthcare in Asia Pacific

The digitalization of healthcare in Asia Pacific is being utilized to enhance the patient-centered approach and expanding access to health. In a candid conversation with Abhishek Shah, CEO at Wellthy Therapeutics, Ed Cox, Executive Vice President, Strategic Alliances & Global Head of Digital Medicine at EVERSANA, uncovered the current healthcare landscape and how digital strategy […]

The Regulatory Landscape in Digital Health

Despite the advances in digital health and digital therapeutics in recent years, there remains an ambiguity in the digital space and uncertainty surrounding regulation and reimbursement of digital technologies applied to pharma, biopharma and medical device companies. In an insightful conversation that was part of EVERSANA’s Digital Symposium, Ed Cox, Executive Vice President, Strategic Alliances […]

Access to Technology and the Rise of Digital Health in Asia Pacific

The access to technology, development of telehealth and evolution of digital therapeutics are thriving in Asia Pacific; and pharmaceutical companies are levering the momentum to reach to a broader segment of the patient population. Ed Cox, Executive Vice President, Strategic Alliances & Global Head of Digital Medicine at EVERSANA, interviewed Anish Shindore, Head of Digital […]

Digital Innovation in Asia Pacific

Digital medicine and digital therapeutics are transforming the healthcare industry by changing the care delivery format, and they have the potential to improve patient adherence and outcomes. In our recent Digital Symposium, Ed Cox, Executive Vice President, Strategic Alliances & Global Head of Digital Medicine at EVERSANA, interviewed David Keene, CEO at IntroSpect Digital Therapeutics […]

Outlook: Digital & Pharma in Asia Pacific

Asia Pacific is one of the fastest-growing regions for digital innovation in the pharmaceutical and biotechnology industries. Its promising outlook is mainly driven by necessity, commercial flexibility and a broad talent pool. In a candid conversation broadcasted during the EVERSANA’s Digital Symposium, Ed Cox, Executive Vice President, Strategic Alliances & Global Head of Digital Medicine, […]

Insights from ISPOR 2020

Shaping the future of patient care. From a panel discussion to podium and workshop presentations, EVERSANA shared insight at this year’s virtual ISPOR 2020 conference. More than 1,300 attended the conference from 54 countries; and our experts demonstrated the impact of comprehensive HEOR capabilities, including economic modeling, evidence synthesis, value communication and reimbursement strategies, across […]

Leading and Decision-Making in Uncertain Times

By definition, leaders must have followers, who are defined as people who must be shown the way. While this is within most leaders’ grasps when the road ahead is straight and wide and the destination is visible, more is demanded of them when the road splits, narrows and dusk falls. The current crisis presents special […]

5 Trends in Digital Medicine to Watch For

  We Are Uniquely Positioned To Deliver EVERSANA is uniquely positioned to follow the trends and introduce new models and strategies to maximize the value of pharmaceutical products through Digital Medicine Solutions and Execution. Digital Solutions can be deployed to impact the entire life cycle of a product in unprecedented ways. Schedule a 30-minute call […]

PharmaVOICE Outsourcing Showcase

The New Roaring 20s: How Outsourced Commercialization is the Revolution We Need. To effectively commercialize a product, traditional service silos stand in the way of true healthcare transformation. Do disparate service providers look at the life cycle in the same way you do? There is a real need for a market access strategy that converts […]

A Patient Hero

Making the Patient an Extension of the Team The concept of patient-centricity is well embedded throughout EVERSANA and is intrinsically tied to helping the agency’s clients achieve their goals. Kristin LaBounty Phillips believes that the entire agency — with a unified commitment to quality in addressing patients’ needs — embodies the concept of “patient hero.” […]

Realizing Value from Digital in the Healthcare Environment [Slides]

[Presentation Slides] The advancements of Digital Therapies are promising but commercial success is not always guaranteed. This presentation explores the pitfalls and challenges of selling products into the uniquely complicated and regulated healthcare market. It will lay the groundwork for digital companies to have successful commercial strategies and be able to: Answer questions like: What […]

Realizing Value from Digital in the Healthcare Environment [Webinar]

[WEBINAR – 20 MINUTES] The advancements of Digital Therapies are promising but commercial success is not always guaranteed. This presentation explores the pitfalls and challenges of selling products into the uniquely complicated and regulated healthcare market. It will lay the groundwork for digital companies to have successful commercial strategies and be able to: Answer questions […]

The New Roaring 20s: How Outsourced Commercialization is the Revolution We Need

The “Great Gatsby Era” was an exciting time of new prosperity, infinite creativity and dramatic social change. Long-standing social norms and traditions gave way to the “mass culture” and consumerism that modernized American society. “What will they think of next?” was a popular expression that defined the era. On the 100-year anniversary of this revolutionary […]

Trends Disrupting Life Sciences in 2020

From the commercialization of digital medicines to the evolution of value-driven healthcare – our thought leaders deliver insight on the trends impacting the life science industry that will continue to shape our thinking well in 2020 and beyond. Take a look at the trends we’re tracking by clicking on the links below: The Transformative Promise […]

Ask the Expert – Digital Therapeutics

From reimbursement strategies, distribution, dispensing, patient engagement and adherence programs, EVERSANA offers integrated solutions to alleviate the barriers facing the adoption of digital therapeutics. Mike Ryan, Executive Vice President of Europe and Asia Pacific, discusses how EVERSANA is leading the commercialization of digital therapeutics with an innovative and nimble commercial model valuable to patients, providers […]

WHAT IF… We Broke the Silos Throughout Pre- to Post-Commercialization?

In their special November/December issue, PharmaVOICE asked industry leaders to think beyond the status quo and provide insight into what needs to happen to achieve aspirational goals and evolve the healthcare industry in 2020. In the feature article titled, What if…” PharmaVOICE turns to their community of thought leaders to weigh in on their own […]

After FDA Approval, Can Gene Therapies Achieve Marketing Success?

Without a doubt, gene therapy is transforming healthcare by revolutionizing patient care from conventional treatment models to curative therapy models. There are more than 7,000 distinct types of rare and genetic diseases and 400+ million individuals suffering from a rare disease. With a market that is fragmented, there is a need for an innovative, end-to-end […]

Building a Service Offering from the Research Lab to the Patient’s Home

A Conversation with Pharmaceutical Commerce & Jim Lang, Chief Executive Officer, EVERSANA Not quite a year ago, an assemblage of pharma service providers came into being as EVERSANA. Funded by two private equity firms with a background in healthcare—Water Street Healthcare Partners and JLL Partners, there were six acquisitions at the time: Dohmen Life Science […]

Are We Transforming In The Right Way?

Why Product Launches Can’t Be Distracted By Empty Promises. We can all agree that innovations in therapeutic development have advanced beyond traditional product launch strategies and service models. In every step of the product lifecycle, we see pockets of transformation. The problem is exactly that – “pockets” of transformation. Your product launch strategy has to […]

Driving the Commercialization of Regenerative Medicine

With more than 7,000 distinct types of rare and genetic diseases and 400+ million individuals suffering from a rare disease, regenerative medicine holds the hope for a cure – transforming healthcare by revolutionizing patient care from conventional treatment models to curative therapy models. With the advancement of new technologies coupled with the creation of new […]

Top-100-canva
EVERSANA, Patient Experience Project featured in MM&M July Issue

Each year, Medical Marketing & Media compiles a list of the top 100 medical marketing agencies in North America. As MM&M Editor Stephen Madden shares at the opening of the July issue, “A typical issue of MM&M has 56 pages; with 244, this beast has almost five times as many.” From agencies A to Z, […]

no-image
Gene Therapy for Rare Disorders

With only three approved products in the marketplace, how do we build a regenerative medicine ecosystem that delivers more value to patient’s faster?

no-image
Insights from AMCP 2019

EVERSANA attended (and sponsored) The Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting. If you missed the conference, here are a few key takeaways from our colleagues who attended: 1) Federal and State Legislature Update Increases in federal and state policies are putting more pressure on drug prices The possible removal […]

Product Master Data Management

This white paper shares considerations, common pitfalls and key takeaways for manufacturers participating in Medicaid. Recent market and enforcement trends in healthcare further exemplify the transition from a volume to value-based marketplace, as well as the complexities to contain the increasing costs of drugs in the new paradigm. The costs of branded prescription drugs are rising […]

Interested in scheduling a meeting or speaking event?

Contact Us

  • This field is for validation purposes and should be left unchanged.